HealthCor Management L.P. Has $20.41 Million Stake in The Medicines Company (MDCO)

HealthCor Management L.P. reduced its stake in shares of The Medicines Company (NASDAQ:MDCO) by 32.0% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 682,200 shares of the company’s stock after selling 321,748 shares during the quarter. HealthCor Management L.P. owned 0.92% of The Medicines worth $20,405,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. OppenheimerFunds Inc. grew its holdings in shares of The Medicines by 0.3% during the 2nd quarter. OppenheimerFunds Inc. now owns 707,160 shares of the company’s stock worth $25,953,000 after purchasing an additional 1,777 shares in the last quarter. State of Wisconsin Investment Board lifted its position in shares of The Medicines by 2.6% during the 2nd quarter. State of Wisconsin Investment Board now owns 70,100 shares of the company’s stock worth $2,573,000 after buying an additional 1,800 shares during the last quarter. Aperio Group LLC lifted its position in shares of The Medicines by 8.5% during the 2nd quarter. Aperio Group LLC now owns 28,013 shares of the company’s stock worth $1,028,000 after buying an additional 2,203 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in shares of The Medicines by 24.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 13,095 shares of the company’s stock worth $481,000 after buying an additional 2,550 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System lifted its position in shares of The Medicines by 7.4% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 43,419 shares of the company’s stock worth $1,593,000 after buying an additional 2,990 shares during the last quarter.

The Medicines stock opened at $19.06 on Friday. The company has a debt-to-equity ratio of 31.23, a quick ratio of 2.40 and a current ratio of 2.41. The Medicines Company has a 12 month low of $18.64 and a 12 month high of $41.57.

The Medicines (NASDAQ:MDCO) last posted its earnings results on Thursday, November 8th. The company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.13). The firm had revenue of ($3.30) million during the quarter, compared to the consensus estimate of $1.88 million. The Medicines had a negative net margin of 668.93% and a negative return on equity of 1,477.75%. The Medicines’s revenue for the quarter was down 141.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.19) earnings per share. Equities research analysts anticipate that The Medicines Company will post -2.91 EPS for the current year.

Several analysts recently weighed in on MDCO shares. Oppenheimer set a $50.00 price objective on The Medicines and gave the stock a “buy” rating in a research report on Monday, September 24th. Citigroup upped their price objective on The Medicines from $40.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, August 20th. Cowen set a $46.00 price objective on The Medicines and gave the stock a “buy” rating in a research report on Sunday, November 11th. ValuEngine downgraded The Medicines from a “buy” rating to a “hold” rating in a research report on Monday, September 24th. Finally, BidaskClub downgraded The Medicines from a “buy” rating to a “hold” rating in a research report on Tuesday, August 28th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $49.67.

In other news, EVP Christopher T. Cox bought 50,300 shares of the company’s stock in a transaction on Friday, November 16th. The stock was purchased at an average cost of $19.73 per share, for a total transaction of $992,419.00. Following the completion of the transaction, the executive vice president now owns 60,308 shares of the company’s stock, valued at $1,189,876.84. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. 10.29% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: “HealthCor Management L.P. Has $20.41 Million Stake in The Medicines Company (MDCO)” was posted by WKRB News and is the property of of WKRB News. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.wkrb13.com/2018/12/16/healthcor-management-l-p-has-20-41-million-stake-in-the-medicines-company-mdco.html.

The Medicines Company Profile

The Medicines Company, a biopharmaceutical company, provides medicines to treat acute and intensive care patients. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention in the United States.

See Also: Marijuana Stocks

Institutional Ownership by Quarter for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply